Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6167307 | 0.94 | ALDH1A1 (0.57) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL6168566 | 0.92 | ALDH1A1 (0.60) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL6166639 | 0.92 | ALDH1A1 (0.60) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL7238882 | 0.87 | — | — | |
| SCHEMBL11330132 | 0.83 | NR1I2 (0.79) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL11330152 | 0.83 | NR1I2 (0.79) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL27476413 | 0.82 | CYP1A2 (0.70) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL8915341 | 0.81 | NR1I2 (0.59) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL3964566 | 0.81 | NR1I2 (0.59) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL10405954 | 0.81 | NR1I2 (0.59) | NR1I2PGRADORA3PTGS2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895565-B2 | Heterocyclic compound and use of the same | NISHIO TETSUYA (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20110319618-A1 | HETEROCYCLIC COMPOUND AND USE OF THE SAME | NISHIO TETSUYA (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-0888271-B1 | BENZAMIDINE DERIVATIVES SUBSTITUTED BY AMINO ACID AND HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6242454-B1 | Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants | BERLEX LABORATORIES INC. | 2001-06-05 | — | — | US | disclosed |
| US-6071912-A | INHIBIT HUMAN FACTOR XA AND ARE THEREFORE USEFUL AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF DISEASE-STATES CHARACTERIZED BY THROMBOTIC ACTIVITY; AMINO-, OXY- AND THIA-SUBSTITUTED TRIAZINES | BERLEX LABORATORIES, INC. (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0888271-A4 | BENZAMIDINE DERIVATIVES SUBSTITUTED BY AMINO ACID AND HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2000-03-15 | — | — | EP | disclosed |
| US-5994375-A | ANTICOAGULANTS | BERLEX LABORATORIES, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0888271-A1 | BENZAMIDINE DERIVATIVES SUBSTITUTED BY AMINO ACID AND HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997029067-A1 | BENZAMIDINE DERIVATIVES SUBSTITUTED BY AMINO ACID AND HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (DE) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319618-A1 | HETEROCYCLIC COMPOUND AND USE OF THE SAME | CYP2D6, CYP2B6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | NR1I2 698/4885PGR 2413/4885ADORA3 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.